SFJ V (Pfizer)

SFJ V and Pfizer collaborated on Phase III studies for Besponsa® (inotuzumab), a late-stage product for the treatment of acute lymphoblastic leukaemia. The antibody-drug conjugate was approved for this indication in the US and Europe in 2017.